secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-06-05T20:38:13+00:00
Accession:  0001628280-26-041298
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vanda shareholders re-elect three Class II directors and approve equity plan amendment
--------------------------------------------------------------------------------

- Directors Dugan, Duncan, and Ward re-elected with majority support; broker non-votes of ~10M shares.
- Shareholders ratified PwC as auditor for FY 2026 with 48.1M votes for.
- Advisory say-on-pay passed; ~35.2M for, ~3.2M against.
- Amendment to 2016 Equity Plan to increase authorized shares approved with 31.7M for, 6.7M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/0001628280-26-041298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/vnda-20260604.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-041298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer